|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-6-20
|
|
pubmed:abstractText |
Use of unboosted atazanavir (ATV) with tenofovir disoproxil fumarate (TDF), although attractive from a clinical view point, has not been tested in trials and is not currently recommended because of the risk of suboptimal ATV pharmacokinetics (PK). In order to improve ATV exposure, plasma and intracellular (IC) PK of ATV in patients administered with ATV 400 mg once daily and TDF/emtricitabine (FTC) and switched to ATV 200 mg twice daily were studied.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
2040-2058
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
499-504
|
|
pubmed:meshHeading |
pubmed-meshheading:21685537-Adenine,
pubmed-meshheading:21685537-Adult,
pubmed-meshheading:21685537-Anti-HIV Agents,
pubmed-meshheading:21685537-Deoxycytidine,
pubmed-meshheading:21685537-Drug Administration Schedule,
pubmed-meshheading:21685537-Drug Therapy, Combination,
pubmed-meshheading:21685537-HIV Seropositivity,
pubmed-meshheading:21685537-HIV-1,
pubmed-meshheading:21685537-Humans,
pubmed-meshheading:21685537-Male,
pubmed-meshheading:21685537-Middle Aged,
pubmed-meshheading:21685537-Oligopeptides,
pubmed-meshheading:21685537-Phosphonic Acids,
pubmed-meshheading:21685537-Pyridines,
pubmed-meshheading:21685537-Reverse Transcriptase Inhibitors,
pubmed-meshheading:21685537-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients.
|
|
pubmed:affiliation |
Department of Infectious Diseases of the University of Torino, Amedeo di Savoia Hospital, Torino, Italy. stefano.bonora@unito.it
|
|
pubmed:publicationType |
Journal Article
|
